Table 1.
Schematic overview of studies involving acetysalicylic acid in human experimental pain models
| Reference | Dose | Model (pain assessments) | Main findings | |
|---|---|---|---|---|
| Acute models | [10] (n= 30) | Topical application (0.03–5%) | Intradermal continuous infusion of phosphate buffered solution (pH 5.2) VAS | Doses > 1.5% VAS↓ |
| [8] (n= 32) | 1000 mg p.o. | Intracutaneous electrical stimulation VAS, evoked brain potentials | VAS ↓, amplitudes of evoked potentials ↓ latencies of evoked potentials ↔ | |
| [13] (n= 14) | 1000 mg i.v. | Stimulation of nasal mucosa by CO2 VAS, evoked brain potentials, power spectrum | PDT ↔ | |
| Amplitudes and latencies of evoked potentials ↓, power spectrum changed | ||||
| [9] (n= 9) | 750 mg p.o. | Laser skin stimulation, evoked brain potentials | Amplitude ↓ | |
| [14] (n= 24) | 600 and 900 mg p.o. | Ischaemic pain AUCVAS, PTT | No parameters were affected | |
| [12] (n= 10) | 1200 mg p.o. | Electrical stimulation of dental pulp PDT | PDT ↑ | |
| Models inducing hyperalgesia | [16] (n= 60) | 900 mg p.o. | Delayed-onset muscle soreness VAS, McGill questionnaire, deep pressure PDT | No parameters were affected |
| [15] (n= 10) | Topical application (0.25 g ml−1) | Topically applied capsaicin, evoked pain, area of secondary HA to pinprick and heat and allodynia to light touch | Area of HA to pinprick and allodynia to light touch↓ | |
| Area of HA to heat ↔ | ||||
| [11] (n= 12) | 100 and 1500 mg p.o. | Long-lasting pinching of the interdigital web (two different intensities) PDT | PDT ↑ | |
| Only the highest intensity discriminated between doses |
In the column ‘Model’ the method for pain assessment is normal font, and the method for pain induction is bold. PDT, pain detection threshold; PTT, pain tolerance threshold; AUC, area under curve; VAS, visual analogue scale; HA, hyperalgesia.